Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00324454 · ClinicalTrials.gov registry record · Phase 2
Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease
A Phase 2 study of Amyotrophic Lateral Sclerosis and Motor Neuron Disease, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00324454: Completed Phase 2 study of Amyotrophic Lateral Sclerosis and Motor Neuron Disease, sponsored by Duke University.
NCT00324454 is a Phase 2 study of Amyotrophic Lateral Sclerosis and Motor Neuron Disease that has completed, run by Duke University. The registered enrollment target is 20 participants, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00324454, a Phase 2 study of Amyotrophic Lateral Sclerosis and Motor Neuron Disease, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Levetiracetam (Keppra) is used to treat partial onset seizures. Its biological effects suggest it might also be useful in treating 3 aspects of human motor neuron diseases (MNDs) for which no effective therapy exists: cramps, spasticity, and disease progression.
Conditions Studied
Interventions
- BIOLOGICAL Levetiracetam
Study Locations (1)
North Carolina
- Duke University ALS Clinic - 932 Morreene Road - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
What the finished NCT00324454 record still lists
NCT00324454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Levetiracetam is the first listed.
NCT00324454 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00324454 about?
NCT00324454 is a clinical study titled "Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease". Levetiracetam (Keppra) is used to treat partial onset seizures. Its biological effects suggest it might also be useful in treating 3 aspects of human motor neuron diseases (MNDs) for which no effective therapy exists: cramps, spasticity, and disease progression.
What is the current status of trial NCT00324454?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2006-05. Estimated completion is 2008-06.
What conditions does trial NCT00324454 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Primary Lateral Sclerosis, Progressive Muscular Atrophy.
What interventions are being tested in trial NCT00324454?
The interventions under investigation include: Levetiracetam (BIOLOGICAL).
Who is sponsoring clinical trial NCT00324454?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00324454 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00324454's enrollment target sits among peer trials
20 78th of 102 higher than 23 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia